—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Scholar Rock Holding Corp (SRRK) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for SRRK, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 53/100 · S&P 500 fund at 45, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-30
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.1% over 20 sessions. Factor regime → 2026-09-30
  • Sector × region Health care in US: −2.2% week · −2.8% month · +1.9% quarter · +11.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-02
  • Sovereign pressure Index 0.58 · down 0.32 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-01
How it trades on rate days beta 0.78 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How SRRK has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.78 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Scholar Rock Holding Corp moved 0.78% on average · correlation 0.12 · higher than 75% of US names
  • Beta, last 3 months 1.32 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.82% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −2.49% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against SRRK on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Scholar Rock Holding Corp

SRRK in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Scholar Rock develops antibody drugs that target the latent, or inactive, forms of growth factors in the TGF-beta family, aiming to treat rare neuromuscular diseases. Its lead candidate, apitegromab, blocks myostatin activation and is in mid-stage trials for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Other candidates in earlier trials target latent TGF-beta for solid tumours, fibrotic disease and iron-restricted anaemia. The company is based in Cambridge, Massachusetts, and listed in the United States since 2018.
Where it sits in the stack
Scholar Rock carries no seat in our index and sits outside the AI build-out layers the diary tracks; it belongs to the healthcare sector, within the biotechnology industry, among clinical-stage developers of neuromuscular and growth-factor therapies.
Who it is priced against
The diary has no assigned peer group for this name; the market sometimes compares it with Biogen, which also develops treatments for neuromuscular disease.
Why Closelooknet tracks it
Scholar Rock holds no index seat and carries no Closelooknet score, and it has not appeared in any edition or quote so far.
What the diary watches
Whether trial data on apitegromab or the other pipeline candidates changes sentiment, given the stock's recent slide below its short-term average and its downgrade from analysts.

Scholar Rock Holding Corp (SRRK) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 25/100 composite (momentum 44, quality 1, valuation —) across 6 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 7 analyst actions on the wire · latest: price target by Truist, 2026-09-24

The Street on this name

Analyst actions and the latest print for SRRK from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 77 from 76 Target raised to $77 from $76 (+57.8% to spot) 2026-09-24
  • Price target Evercore ISI — target 72 from 65 Target raised to $72 from $65 (+49.2% to spot) 2026-09-15
  • Price target Wedbush — target 70 from 64 Target raised to $70 from $64 (+45% to spot) 2026-09-15

7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What SRRK pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +14.9% in FY2025 76 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-02

Quick answers

What is Scholar Rock Holding Corp (SRRK)?

Scholar Rock Holding Corp trades as SRRK on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-02.

Is SRRK in a Closelooknet index?

Not currently — Scholar Rock Holding Corp is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-02.

What is Scholar Rock Holding Corp's Closelooknet composite score?

25 out of 100, with momentum 44, quality 1 and valuation n/a sub-scores, as of 2026-10-02. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does SRRK trade against its moving averages?

Mixed moving-average stack: Trades -11.5% vs the 50-day and -4.6% vs the 200-day average, 25.3% below the 52-week high and +70.5% off the 52-week low. Computed from daily closes. As of 2026-10-01 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Scholar Rock Holding Corp trade when bond yields rise?

Over the past year Scholar Rock Holding Corp had a beta of 0.78 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 75% of US names. On the 10 sessions in which long bonds fell most it moved −1.82% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Scholar Rock Holding Corp do?

Scholar Rock develops antibody drugs that target the latent, or inactive, forms of growth factors in the TGF-beta family, aiming to treat rare neuromuscular diseases. Its lead candidate, apitegromab, blocks myostatin activation and is in mid-stage trials for spinal muscular atrophy and facioscapulohumeral muscular dystrophy. Other candidates in earlier trials target latent TGF-beta for solid tumours, fibrotic disease and iron-restricted anaemia. The diary has no assigned peer group for this name; the market sometimes compares it with Biogen, which also develops treatments for neuromuscular disease.

Where does Scholar Rock Holding Corp sit in the AI build-out?

Scholar Rock carries no seat in our index and sits outside the AI build-out layers the diary tracks; it belongs to the healthcare sector, within the biotechnology industry, among clinical-stage developers of neuromuscular and growth-factor therapies. Scholar Rock holds no index seat and carries no Closelooknet score, and it has not appeared in any edition or quote so far.

Does Scholar Rock Holding Corp pay a dividend?

No cash distribution shows in Scholar Rock Holding Corp’s price series over the last three years. The share count rose 14.9% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Scholar Rock Holding Corp recently?

The most recent analyst action on Scholar Rock Holding Corp on the Closelooknet wire is a price target by Truist on 2026-09-24 (target 77 from 76). 7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for SRRK, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.